In a change-of-pace episode, Chadi has the tables turned on him as he is interviewed by two supporters and reviewers of his new book “Toxic Exposure: The True Story behind the Monsanto Trials and the Search for Justice.” Kelly Ryerson, MBA, GlyphosateGirl.com, and Mikkael Sekeres, author of “Drugs and the FDA: Safety, Efficacy, and the Public’s Trust” and “When Blood Breaks Down: Life Lessons from Leukemia,” ask Chadi to comment on why he was chosen as an expert witness, how glyphosate causes cancer and how much exposure is needed to cause lymphoma, why Roundup is able to stay on the market to this day, and what it was like to take the stand and answer questions from the Monsanto lawyers, among so much more.
Dr. Simrit Parmar, founder of Cellenkos, joins the show to discuss her journey from the lab to the biotech startup world, detailing the inspiration behind launching her company, the challenges of securing funding, and the resilience required to overcome rejections. She shares insights into Cellenkos’ lead product, its progress toward market approval, and the rigorous
Carol Rausch—a healthcare professional, cancer researcher, and former patient with lymphoma—shares how her journey from researcher to patient transformed her understanding of medical language. She discusses the impact of word choice on patients, why certain battle and war metaphors can be harmful, and how language used in clinical settings differs from what resonates with those
Drs. David Braun and Toni Choueiri join to discuss a groundbreaking Nature study on a personalized neoantigen vaccine for adjuvant renal cell carcinoma. They explore the inspiration behind the trial, how the vaccine was developed and administered, and its safety profile. The conversation also covers patient outcomes after 3-4 years, including immune responses and disease
